QNRX | Quoin Pharmaceuticals, Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	6.28 - 6.95
52 Week Range	5.01 - 54.95
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	48,102
Average Volume	234,836
Shares Outstanding	255,661
Market Cap	1,730,441
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-08-01

Valuation
Profitability
Growth
Health
P/E Ratio	-0.10
Forward P/E Ratio	N/A
EPS	-66.85
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	4
Country	USA
Website	QNRX

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

QNRX's peers: ADTX, ALLR, APVO, ATHE, NTRB, CMMB, COCP, ABVC, EDSA, CELZ, ENSC, EQ, EVAX, GTBP, GOVX, HOTH, IKT, INDP, INM, KPRX, KTTA, KZIA, LGVN, LIXT, NLSP, NNVC, NRSN, NRXP, PSTV, PTN, BWV, PXMD, REVB, HILS, VRAX, NRBO, KRBP, BDRX, UNCY, CDIO, RNXT, SABS, SIDU, SPRC, TENX, TLSA, TTNP, VS, VTGN, VTVT, XRTX, OKYO, SNTI, IMNN, ICU, CMND, DOMH, CVKD

*Chart delayed

Analyzing fundamentals for QNRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see QNRX Fundamentals page.

Watching at QNRX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on QNRX Technicals page.